GlobeNewswire

UPDATE -- Trado GmbH Announces That Berlin Court Intervenes and Grants Preliminary Injunction Against Matthias Woestmann and Associates, Who Lost Millions of Envion Investor Money

Dela

Trado GmbH / UPDATE -- Trado GmbH Announces That Berlin Court Intervenes and Grants Preliminary Injunction Against Matthias Woestmann and Associates, Who Lost Millions of Envion Investor Money . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Victory for Envion Founders, As Quadrat Capital and Sycamore GmbH, Controlled by Woestmann, Thomas van Aubel, and Jutta Freifrau von Falkenhausen, Receive Setback

BERLIN, June 07, 2018 (GLOBE NEWSWIRE) -- The following are statements issued by Trado GmbH: Matthias Woestmann and his business associates, through their investment vehicles Quadrat Capital and Sycamore GmbH, received a striking blow on Tuesday from a Berlin judge in a ruling that may be the first of many setbacks for the current majority owners of Swiss blockchain infrastructure company envion AG. A preliminary injunction filed on behalf of envion's founders - led by Michael Luckow through the founders' company Trado GmbH - who claim rightful ownership of envion, was granted on Tuesday, June 5th, 2018.

Actions taken by Woestmann and the others follow a pattern used with previous companies involved in scandals across Germany. Evidence seen by the Berlin court was sufficient for the judge to rule that envion shares cannot be sold or traded to any 3rd party. The ruling further forbids envion's unlawful shareholders from transferring or debiting any of envion's assets. Envion's founders have stated that they will continue to file lawsuits in both German and Swiss courts until their majority is restored. The next court date is scheduled for June 21st.

The owners of the two holding companies (Quadrat Capital GmbH and Sycamore GmbH), Matthias Woestmann, Thomas van Aubel, Jutta Freifrau von Falkenhausen, and Dinnies von der Osten, have a history of profiting from investments in companies that fail spectacularly and under suspicious circumstances. They and their associates are linked to a long list of companies involved in some of Germany's largest financial scandals, including IGB, Balda (renamed to Clere), Q-cells, and Solon. 

Mistakes made while executing the takeover of envion, which raised $100 million in an ICO in January, may keep envion from being their latest victim. Instead of a legal corporate takeover, Woestmann violated a contract which explicitly forbade him from actions compromising the majority ownership of the founders. Woestmann's inaction since the takeover has resulted in millions of dollars in lost dividends for investors and the founders being blocked from operating the company.

"Woestmann's serious missteps now threaten to bring his and his confederates' house of cards crashing down because he illegally created extra shares via an unauthorized capital increase which he then gave to Sycamore," said Michael Luckow, one of the founders of envion who have taken legal action against Woestmann and his associates.

Speaking to Swiss news service SWI, Woestmann did not deny charges that his actions were illegal when he diluted the founders' shares. Envion investors reported that he admitted his guilt in a call on May 28th which was widely discussed within the envion investor community, stating that he expected that he would be found guilty and would be liable for damages. 

When solicitations distributed by Woestmann for bids to buy envion were attained by the founders, they moved quickly to file the court injunction. Documents show Woestmann attempting to sell envion for use as a "holding structure for new businesses to separate envion (sic) balance sheet from profitable businesses" and advertising that the "existing investor base can be used for all kinds of [other] business models" apart from the business that investors supported with $100 million.

About Trado GmbH

Trado GmbH holds the founders' shares in envion AG, a German-Swiss company that has developed a disruptive datacenter concept for crypto mining: a system of container-based mobile units that can be deployed right at the source of energy, either at the solar photovoltaic (PV) park or the power plant, providing the required flexibility for today's energy markets. Information about Trado and envion's founders can be found at www.envion-founders.org. 

Contact:

Chris Pfaff Tech Media LLC
Chris Pfaff
Phone: +1-201-218-0262
Email: chris@chrispfafftechmedia.com 

NAÏMA Strategic Legal Services GmbH
Uwe Wolff
phone: +49 30 2404 8290
email: uwe.wolff@naima-media.de




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Trado GmbH via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

Corline Biomedical AB: Rekryterar Lars Olsson som Head of CMC14.2.2019 12:44:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man rekryterat Lars Olsson till den nyinrättade tjänsten som Head of CMC (Chemistry, Manufacturing & Control). Lars Olsson hade tidigare samma tjänst hos Wilson Therapeutics AB, som under 2018 förvärvades av amerikanska Alexion. Lars Olsson kommer att ansvara för Corlines samtliga aktiviteter inom tillverkning och kontroll relaterat till bolagets läkemedelsprodukter, med särskilt fokus på Renaparin® inför kommande fas 2- och fas 3-utveckling. I slutet av 2018 meddelade Corline att patientrekryteringen startar i bolagets fas 1-studie RENAPAIR 01, där produkten Renaparin®, som är under utveckling för att förbättra utfallet av njurtransplantation, utvärderas med avseende på tolerabilitet och säkerhet. Därmed tog en ny utvecklingsfas vid i bolaget i vilken alltmer resurser fokuseras på att förbereda den fortsatta kliniska utvecklingen av produkten genom fas 2 och fas 3 i syfte att slutligen kunna registrera produkten för k

Arcoma AB: Canon och Arcoma tecknar distributörsavtal för Turkiet14.2.2019 10:38:00Pressmeddelande

14 februari 2019 Canon Medical Systems i Turkiet och Arcoma har tecknat ett distributörsavtal som gör att Canon kommer att kunna sälja Arcomas produkter i Turkiet från och med den 15 februari 2019. Canon är sedan tidigare återförsäljare för Arcomas produkter i Nordamerika och utvalda länder i Europa. Detta samarbete utökas nu till Turkiet som är det första land i Canons Asien organisation att välja Arcoma som en formell partner. "Att vi stärker och formaliserar samarbetet med Canon även i Turkiet är ännu ett erkännande av Arcoma som leverantör av högkvalitativa röntgensystem. Canon i Turkiet förbereder ett flertal större upphandlingar till sjukhus där Arcomas lösningar ingår. Avtal som detta ingår i Arcomas strategi att utöka med nya försäljningskanaler och att expandera till nya länder för att skapa framtida tillväxt." kommenterar Arcomas VD, Jesper Söderqvist. För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soder

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North12.2.2019 09:00:00Pressmeddelande

STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French investment management company Alto Invest have taken part in the private placement. OssDsign will now begin the process towards a listing on Nasdaq First North in 2019. The proceeds from the private placement will be used for continued sales expansion in Europe and the US of OssDsign regenerative implant solutions for improved healing of bone defects. Moreover, funds will be used for entering new markets, primarily preparing for market introduction in Japan where the company in parallel to the regulatory process will initiate pre marketing activities. With ethical committee approval already in place, leading surgeons in Japan can start building experience with the OssDsign technology prior to regulatory approval and launch. OssDsign prepares for a listing on Nasdaq Stockholm First North in 2019.

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum